Comparison of short- and long-term effectiveness of ixekizumab and secukinumab in real-world practice

References

• Kim IH, West CE, Kwatra SG, et al. Comparative efficacy of biologics in psoriasis: a review. Am J Clin Dermatol. 2012;13(6):365–374.
   PubMed Web of Science ®Google Scholar
• Silfvast-Kaiser A, Paek SY, Menter A. Anti-IL17 therapies for psoriasis. Expert Opin Biol Ther. 2019;19(1):45–54.
   PubMed Web of Science ®Google Scholar
• Farahnik B, Beroukhim K, Nakamura M, et al. Anti-IL-17 agents for Psoriasis: a review of phase III data. J Drugs Dermatol. 2016;15(3):311–316.
   PubMedGoogle Scholar
• Lee EB, Amin M, Egeberg A, et al. Drug survival of secukinumab for psoriasis in a real-world setting. J Dermatolog Treat. 2019;30(2):150–151. .
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Burlando M, Caldarola G, et al. Ixekizumab effectiveness and safety in the treatment of moderate-to-severe plaque Psoriasis: a multicenter, retrospective observational study. Am J Clin Dermatol. 2020;21(3):441–447. .
   PubMed Web of Science ®Google Scholar
• Egeberg A, Bryld LE, Skov L. Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2019;81(1):173–178.
   PubMed Web of Science ®Google Scholar
• Sawyer LM, Malottki K, Sabry-Grant C, et al. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. PLoS One. 2019;14(8):e0220868.
   PubMed Web of Science ®Google Scholar
• Fredriksson T, Pettersson U. Severe psoriasis–oral therapy with a new retinoid. Dermatologica. 1978;157(4):238–244.
   PubMedGoogle Scholar
• Costanzo A, Malara G, Pelucchi C, et al. Effectiveness end points in real-world studies on biological therapies in psoriasis: systematic review with focus on drug survival. Dermatology. 2018;234((1–2)):1–12.
   PubMed Web of Science ®Google Scholar
• Lin PT, Wang SH, Chi CC. Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence. Sci Rep. 2018 30;8(1):16068. .
   PubMedGoogle Scholar
• Warren RB, Smith CH, Yiu ZZN, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the british association of dermatologists biologic interventions register (BADBIR). J Invest Dermatol. 2015;135(11):2632–2640. .
   PubMed Web of Science ®Google Scholar
• Yiu ZZN, Mason KJ, Hampton PJ, et al. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British association of dermatologists biologics and immunomodulators register (BADBIR). Br J Dermatol. 2020;183(2):294–302.
   PubMed Web of Science ®Google Scholar
• Peduzzi P, Concato J, Feinstein AR, et al. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol. 1995;48:1503–1510.
   PubMed Web of Science ®Google Scholar
• Warren RB, Brnabic A, Saure D, et al. Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs secukinumab. Br J Dermatol. 2018;178(5):1064–1071.
   PubMed Web of Science ®Google Scholar
• Sawyer LM, Cornic L, Levin LÅ, et al. Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. J Eur Acad Dermatol Venereol. 2019;33(2):355–366. .
   PubMed Web of Science ®Google Scholar
• Herrera-Acosta E, Garriga-Martina GG, Suárez-Pérez JA, et al. Comparative study of the efficacy and safety of secukinumab vs ixekizumab in moderate-to-severe psoriasis after 1 year of treatment: real-world practice. Dermatol Ther. 2020;17:e13313.
   Google Scholar
• van den Reek JM, Kievit W, Gniadecki R, et al. Drug survival studies in dermatology: principles, purposes, and pitfalls. J Invest Dermatol. 2015;135:e34.
   Web of Science ®Google Scholar
• Spindeldreher S, Maillère B, Correia E, et al. Secukinumab demonstrates significantly lower immunogenicity potential compared to Ixekizumab. Dermatol Ther (Heidelb). 2018;8(1):57–68. .
   PubMed Web of Science ®Google Scholar
• Ohata C, Ohyama B, Katayama E, et al. Real-world efficacy and safety of interleukin-17 inhibitors for psoriasis: A single-center experience. J Dermatol. 2020;47(4):405–408.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Shi N, Burge R, et al. Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab. J Am Acad Dermatol. 2020;82(4):927–935.
   PubMed Web of Science ®Google Scholar
• Rompoti N, Sidiropoulou P, Panagakis P, et al. Real-world data from a single Greek centre on the use of secukinumab in plaque psoriasis: effectiveness, safety, drug survival, and identification of patients that sustain optimal response. J Eur Acad Dermatol Venereol. 2020;34(6):1240–1247.
   PubMed Web of Science ®Google Scholar
• Notario J, Deza G, Vilarrasa E, et al. Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain. J Dermatolog Treat. 2019;30(5):424–429.
   PubMed Web of Science ®Google Scholar
• Torres T, Balato A, Conrad C, et al. Secukinumab drug survival in patients with psoriasis: a multicenter, real-world, retrospective study. J Am Acad Dermatol. 2019;81(1):273–275. .
   PubMed Web of Science ®Google Scholar
• Galluzzo M, Talamonti M, De Simone C, et al. Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation. Expert Opin Biol Ther. 2018;18(7):727–735.
   PubMed Web of Science ®Google Scholar
• Magdaleno-Tapial J, Carmena-Ramón R, Valenzuela-Oñate C, et al. Efficacy and safety of Ixekizumab in a real-life practice: a retrospective bicentric study. Actas Dermosifiliogr. 2019;110(7):585–589.
   PubMed Web of Science ®Google Scholar
• van den Reek JMPA, van Vugt LJ, van Doorn MBA, et al. Initial results of Secukinumab drug survival in patients with Psoriasis: a multicentre daily practice cohort study. Acta Derm Venereol. 2018;98(7):648–654. 201. .
   PubMed Web of Science ®Google Scholar
• van der Schoot LS, van den Reek JMPA, Groenewoud JMM, et al. Female patients are less satisfied with biological treatment for psoriasis and experience more side- effects than male patients: results from the prospective BioCAPTURE registry. J Eur Acad Dermatol Venereol. 2019;33(10):1913–1920.
   PubMed Web of Science ®Google Scholar
• López Jiménez P, Suárez Pérez J, Herrera Acosta E, et al. Secukinumab versus ustekinumab for skin clearance in patients with moderate to severe psoriasis after a year of treatment: real-world practice. Dermatol Ther. 2019;32(4):e12937.
   PubMed Web of Science ®Google Scholar
• Ger TY, Huang YH, Hui RC, et al. Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement. Ther Adv Chronic Dis. 2019 Apr;17(10):2040622319843756.
   Google Scholar